JP2024545741A5 - - Google Patents
Info
- Publication number
- JP2024545741A5 JP2024545741A5 JP2024513739A JP2024513739A JP2024545741A5 JP 2024545741 A5 JP2024545741 A5 JP 2024545741A5 JP 2024513739 A JP2024513739 A JP 2024513739A JP 2024513739 A JP2024513739 A JP 2024513739A JP 2024545741 A5 JP2024545741 A5 JP 2024545741A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding fragment
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/462,795 | 2021-08-31 | ||
| US17/462,795 US11981727B2 (en) | 2021-08-31 | 2021-08-31 | Monospecific and bispecific antibodies and antigen binding fragments thereof |
| PCT/US2022/075723 WO2023034842A2 (en) | 2021-08-31 | 2022-08-31 | Monospecific and bispecific antibodies and antigen binding fragments thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545741A JP2024545741A (ja) | 2024-12-11 |
| JP2024545741A5 true JP2024545741A5 (https=) | 2025-09-02 |
Family
ID=85386669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513739A Pending JP2024545741A (ja) | 2021-08-31 | 2022-08-31 | 単一特異性および二重特異性抗体ならびにその抗原結合断片 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11981727B2 (https=) |
| EP (1) | EP4396226A4 (https=) |
| JP (1) | JP2024545741A (https=) |
| CN (1) | CN118475605A (https=) |
| AU (1) | AU2022337266A1 (https=) |
| CA (1) | CA3230258A1 (https=) |
| WO (1) | WO2023034842A2 (https=) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ503033A (en) | 1997-08-26 | 2003-01-31 | Gliatech Inc | Inhibition of complement activation using anti-properdin agents |
| US7959919B2 (en) | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
| US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| US9745367B2 (en) | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| WO2008134430A1 (en) | 2007-04-24 | 2008-11-06 | Novelmed Therapeutics Inc. | Methods and compositions of inhibiting complement and cellular activation with dextran sulfate |
| US10131706B2 (en) | 2007-08-27 | 2018-11-20 | Novelmed Therapeutics, Inc. | Anti-factor Bb antibodies |
| CN101970002B (zh) | 2007-08-27 | 2016-05-18 | 诺福麦德治疗学股份有限公司 | 用因子Bb特异性抗体抑制补体活化的方法 |
| DK2262831T3 (en) | 2008-03-03 | 2015-04-27 | Novelmed Therapeutics Inc | ANTI-Properdin ANTIBODIES |
| US8664362B2 (en) | 2008-03-03 | 2014-03-04 | NovelMed Therapeutics | Humanized and chimeric anti-properdin antibodies |
| US20140127204A1 (en) | 2010-09-03 | 2014-05-08 | Novelmed Therapeutics, Inc. | Anti-properdin antibodies |
| EP2544694B1 (en) * | 2010-03-02 | 2018-10-31 | Novelmed Therapeutics, Inc. | A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| WO2013102123A2 (en) | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| CA2869477C (en) | 2012-04-03 | 2020-06-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor c3 antibodies and uses thereof |
| US9243070B2 (en) | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor Bb antibodies and uses thereof |
| CA2887050A1 (en) | 2012-10-04 | 2014-04-10 | Novelmed Therapeutics, Inc. | Alternative pathway specific antibodies for treating hemolytic diseases |
| AU2014370404A1 (en) | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| MX2019008827A (es) | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
-
2021
- 2021-08-31 US US17/462,795 patent/US11981727B2/en active Active
-
2022
- 2022-08-31 WO PCT/US2022/075723 patent/WO2023034842A2/en not_active Ceased
- 2022-08-31 CA CA3230258A patent/CA3230258A1/en active Pending
- 2022-08-31 JP JP2024513739A patent/JP2024545741A/ja active Pending
- 2022-08-31 EP EP22865757.3A patent/EP4396226A4/en active Pending
- 2022-08-31 CN CN202280070260.9A patent/CN118475605A/zh active Pending
- 2022-08-31 AU AU2022337266A patent/AU2022337266A1/en active Pending
-
2024
- 2024-05-14 US US18/663,175 patent/US20250042981A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019122405A5 (https=) | ||
| JP2023539245A5 (https=) | ||
| JP2024508671A5 (https=) | ||
| JP2024056687A5 (https=) | ||
| JP2021520832A5 (https=) | ||
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2022512234A5 (https=) | ||
| JP2021514973A5 (https=) | ||
| JP2021503455A5 (https=) | ||
| JP2023134618A5 (https=) | ||
| JP2024156657A5 (https=) | ||
| JP2023071956A5 (https=) | ||
| JP2018510636A5 (https=) | ||
| JP2024059791A5 (https=) | ||
| JP2018093875A5 (https=) | ||
| JP2024086870A5 (https=) | ||
| JP2019505166A5 (https=) | ||
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| JP2019507580A5 (https=) | ||
| CR20240482A (es) | Anticuerpos anti-tl1a y métodos de uso de los mismos | |
| JP2021511387A5 (https=) | ||
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| JP2023549555A5 (https=) | ||
| JP2022500455A5 (https=) | ||
| JP2024012431A (ja) | 抗ｂｃｍａ抗体及びその用途 |